Press release
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report 2024: Strategies And Recent Developments | Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends
The Business Research Company offers in-depth market insights through Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The alpha-1 antitrypsin deficiency augmentation therapy market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population.
The alpha-1 antitrypsin deficiency augmentation therapy market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to telehealth and remote monitoring, precision medicine, gene therapy developments. Major trends in the forecast period include long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, personalized dosing regimens.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp
Market Segmentation:
The main types of products in alpha-1 antitrypsin deficiency augmentation therapy are glassia, aralast NP, prolastin C, zemaira and respreeza. Glassia is a medicine containing human Alpha1-Proteinase inhibitors (Alpha1-PI). It is used to treat adults with lung disease (emphysema) caused by severe alpha1-antitrypsin (Alpha1) deficiency. They are administered through oral, injection and inhalations by hospitals, specialty clinics and others.
Major Driver - Impact Of Rising Respiratory Disease Prevalence On The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
An increase in the number of respiratory diseases is driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy market. Respiratory diseases are disorders that affect the lungs and the respiratory system, leading to breathing difficulties and impaired lung function. Alpha-1 antitrypsin deficiency augmentation therapy aims to treat respiratory diseases by supplementing the deficient protein in individuals with alpha-1 antitrypsin deficiency. The therapy works by restoring the balance of protease-antiprotease activity in the lungs, protecting lung tissue from damage caused by excessive neutrophil elastase activity and reducing inflammation. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the increase in the number of respiratory diseases propels the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.
Competitive Landscape:
Major players in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report
Top Trend - Innovative Recombinant Technology-Based Drug Development Shaping The Ards Market
Major companies operating in the acute respiratory distress syndrome (ARDS) market are focusing on developing innovative therapies, such as recombinant technology-based drug development, to sustain their position in the market. The recombinant DNA technology is used to manufacture therapeutic pharmaceuticals recombinant technology-based drug development. This method includes modifying the DNA of live organisms to synthesize specific proteins. For instance, in March 2022, Inhibrx Inc., a US-based biotechnology company, announced that INBRX-101 had received orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating alpha-1 antitrypsin deficiency (AATD). INBRX-101 is a recombinant human AAT-Fc fusion protein with the potential for a once-monthly dosage. It is intended to safely achieve and maintain levels of AAT found in healthy individuals.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Characteristics
3. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends And Strategies
4. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - Macro Economic Scenario
5. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size And Growth
…..
27. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report 2024: Strategies And Recent Developments | Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC here
News-ID: 3404423 • Views: …
More Releases from The Business Research Company
Global High-Resolution Anoscopy Market Outlook 2025-2034: Trends, Innovations, A …
The High-Resolution Anoscopy Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the High-Resolution Anoscopy Market Size and Projected Growth Rate?
The market size for high-resolution anoscopy has experienced significant growth over the past few years. The market is predicted to increase from $15.03 billion…
Condyloma Acuminata Treatment Market Size Projected To Reach $2.2 Billion By 203 …
"The Condyloma Acuminata Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Condyloma Acuminata Treatment Market Size During the Forecast Period?
In the past few years, the condyloma acuminata treatment market has seen significant growth. The market value, which is anticipated to…
Household Type Fans Market Forecast 2025-2034: Comprehensive Analysis And Growth …
"The Household Type Fans Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Household Type Fans Market?
The market size for household fans has seen consistent expansion in recent years. The projections indicate an increase from $32.22 billion in 2024…
Grain Fumigants Industry Report 2025-2034: Market Dynamics, Trends, And Forecast …
The Grain Fumigants Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Grain Fumigants Market Size During the Forecast Period?
The Grain Fumigants Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This…
More Releases for Antitrypsin
Alpha-1 Antitrypsin Deficiency FDA Approvals, Clinical Trials, and Pipeline 2024 …
DelveInsight's, "Alpha1-Antitrypsin Deficiency Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Alpha1-Antitrypsin Deficiency pipeline landscape. It covers the Alpha-1 Antitrypsin Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alpha-1 Antitrypsin Deficiency pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample…
Alpha 1 Antitrypsin Deficiency Treatment Market Size, Share | Forecast 2032
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Alpha 1 Antitrypsin Deficiency Treatment Market was valued at USD 1.4 Billion in 2018 and is projected to grow at a CAGR of 9.41% to reach USD 2.8 Billion by 2026, over the forecast period.
Market Overview for Alpha 1 Antitrypsin Deficiency Treatment Market
Alpha 1 Antitrypsin Deficiency Treatment Market OverviewAlpha 1 Antitrypsin Deficiency (AATD) treatment market is rapidly evolving due to increasing awareness and advancements in biotechnological research.…
Breathing Easier: Alpha-1 Antitrypsin Deficiency Therapy Market Outlook 2024-203 …
The alpha-1 antitrypsin deficiency augmentation therapy market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population.
The alpha-1 antitrypsin deficiency augmentation therapy market size is expected to see strong growth in…
Alpha1-Antitrypsin Deficiency Treatment Market Growth and Trend Analysis By 2031
Latest "Alpha1-Antitrypsin Deficiency Treatment Market" Size, Share & Trends Analysis Research Report 2024 - By Applications (Auto Sales, Employment Opportunities, Rental Properties, Pets, Other), By Types (Featured ads, Normal ad), By Segmentation analysis, Regions and Forecast to 2031. The Global Alpha1-Antitrypsin Deficiency Treatment market Report provides In-depth analysis on the market status of the Alpha1-Antitrypsin Deficiency Treatment Top manufacturers with best facts and figures, meaning, Definition, SWOT analysis, PESTAL analysis,…
Research Report on Alpha 1 Antitrypsin Deficiency Treatment
Transparency Market Research has published a new report titled, ‘Alpha 1 Antitrypsin Deficiency Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global Alpha 1 Antitrypsin Deficiency Treatment market was valued at around US$ 1.4 Bn in 2018 and is projected to grow at a CAGR of 10.1% from 2019 to 2027.
Read Report Overview: https://www.transparencymarketresearch.com/alpha-1-antitrypsin-deficiency-treatment-market.html
Overview
Alpha-1 antitrypsin (AAT) deficiency is a condition…
Alpha 1-Antitrypsin Deficiency Treatment Market show exponential growth by 2024
Alpha 1-Antitrypsin Deficiency Treatment Market: Overview
Alpha 1-antitrypsin deficiency is an inherited genetic disorder that causes insufficient production of the protein alpha 1-antitrypsin (A1AT) in individuals. A1AT is a protease inhibitor that has the capability to protect body tissues from enzymes of various inflammatory cells such as neurophil elastase. Insufficient production of this protein leads to pulmonary medical complications chronic obstructive pulmonary disease (COPD), cirrhosis and emphysema.
View Report @ http://www.transparencymarketresearch.com/alpha-1-antitrypsin-deficiency-treatment-market.html
At present, the…
